The Princeton-based integrated solutions provider of clinical life science and technology expertise will integrate Saliency’s advanced AI technology into its Imaging Platform to support a growing portfolio of pharmaceutical and medical device clients. The integration will dramatically accelerate image QC and interpretation, enabling rapid development of digital diagnostics and digital therapeutics.
“Clients rely on us for time-sensitive expert-level image interpretation for their clinical trials so they can focus on outcomes,” said Dan Gebow, chief innovation officer at Bioclinica. “We evaluated a variety of medical imaging AI platforms and know the Saliency platform is head and shoulders above others in the market in its ability to deliver value for our clients.”
The Saliency platform uses proprietary algorithms to quickly build and train AI models from a small number of de-identified images. These newly created models can then be used to accurately and efficiently screen, redact, or interpret medical images to support a wide range of therapeutic areas. This capability will be embedded into Bioclinica’s current and future imaging solutions in accordance with EU GDPR and other privacy regulations.
Saliency’s co-founders, Kevin Thomas, MD/PhD, candidate at Stanford University School of Medicine and Łukasz Kidziński, formerly of Stanford’s Bioengineering & Statistics, will join Bioclinica’s Image Science team, further strengthening the company’s medical imaging expertise and offerings.